Innovation
2020 Portfolio Performance
Broadening portfolio with
expanding opportunities
Important Dual-IO opportunity in 1L lung
Multiple Hematology opportunities with the potential to be first-in-class and/or best-in-class
Expanding Immunology portfolio with
Zeposia and TYK 2
* As of June 2021, deucravacitinib is still in Phase III development and subject to clinical trial results and regulatory approval.
2020 product launches
Opdivo: Restoring anti-tumor immune response
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response to fight cancer. Opdivo has become an important treatment option across multiple cancers.
Inrebic: The first once-daily oral therapy
for myelofibrosis
Myelofibrosis is a serious and often debilitating bone marrow disorder for which there has been only one approved treatment option for nearly a decade. The European Commission (EC) granted full marketing authorization for Inrebic (fedratinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. Inrebic is the first once-daily oral therapy to significantly reduce spleen volume and symptom burden for patients with myelofibrosis where treatment with ruxolitinib has failed, who are intolerant to ruxolitinib or who are JAK inhibitor naïve.
CheckMate-9ER: Promising results from
Phase 3 trials
Results from new analyses from the pivotal Phase III CheckMate-9ER trial demonstrated clinically meaningful, sustained efficacy benefits as well as quality of life improvements with the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) compared to sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC).
